Table 1 Baseline patient and disease characteristics

Number of patients

239

241

480

Age (years), mean (SD)

46.7 (12.5)

45.7 (11.3)

46.2 (11.9)

Male, n (%)

121 (50.6)

128 (53.1)

249 (51.9)

White, n (%)

237 (99.2)

241 (100)

478 (99.6)

Body mass index (kg/m²), mean (SD)

28.9 (6.2)

28.9 (6.4)

28.9 (6.3)

Duration of PsA (years), mean (SD)

5.3 (5.9)

6.2 (6.0)

5.8 (6.0)

Swollen joint count (0–66), mean (SD)

14.1 (8.2)

14.0 (8.4)

14.0 (8.3)

Tender joint count (0–68), mean (SD)

26.1 (14.4)

25.1 (13.8)

25.6 (14.1)

Patient pain VAS (0–10), mean (SD)

6.4 (2.1)

6.3 (2.1)

6.3 (2.1)

Patient global disease activity VAS (0–10), mean (SD)

6.3 (2.1)

6.5 (1.9)

6.4 (2.0)

Physician global disease activity VAS (0–10), mean (SD)

6.4 (1.6)

6.2 (1.7)

6.3 (1.6)

≥ 3% BSA psoriasis skin involvement, n (%)

198 (82.8)

196 (81.3)

394 (82.1)

 PASI score (0–72), mean (SD)¹

8.9 (9.0)

11.0 (9.9)

9.9 (9.5)

PASDAS, mean (SD)²

6.7 (1.1)

6.7 (1.1)

6.7 (1.1)

DAPsA, mean (SD)³

72.8 (32.1)

71.8 (34.0)

72.3 (33.0)

CDAI score (0–76), mean (SD)²

34.4 (13.1)

33.3 (12.5)

33.8 (12.8)

HAQ-DI (0–3), mean (SD

1.3 (0.6)

1.3 (0.6)

1.3 (0.6)

C-reactive protein (mg/dL), mean (SD)

2.0 (2.1)

1.9 (2.5)

2.0 (2.3)

Patients with dactylitis, n (%)

124 (51.9)

134 (55.6)

258 (53.8)

 Dactylitis score (1–60)⁴, mean (SD)

9.9 (10.1)

9.3 (9.4)

9.6 (9.7)

Patients with enthesitis, n (%)

181 (75.7)

185 (76.8)

366 (76.3)

 Leeds Enthesitis Index score (1–6)⁴, mean (SD)

3.2 (1.6)

3.0 (1.6)

3.1 (1.6)

Total PsA-modified SHS (0–528), mean (SD)

34.5 (53.5)

35.5 (55.2)

35.0 (54.3)

 Methotrexate, n (%)

173 (72.4)

163 (67.6)

336 (70.0)

  Mean (SD) dose (mg/week)

14.9 (4.8)

14.8 (4.7)

14.8 (4.7)

 Oral corticosteroids, n (%)

67 (28.0)

66 (27.4)

133 (27.7)

  Mean (SD) dose (mg/day)

7.6 (2.5)

7.4 (2.6)

7.5 (2.6)